Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
By R. Levine, M. Wadleigh, J. Cools, Benjamin L. Ebert, G. Wernig, B. Huntly, T. Boggon, I. Wlodarska, Jennifer J. Clark, Sandra A. Moore and 19 more. Cancer Cell, 2005
3,130 citations recorded by the source corpus.
Polycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibrosis (MMM) are clonal disorders arising from hematopoietic progenitors. An internet-based protocol was used to collect clinical information and biological specimens from patients with these diseases. High-throughput DNA resequencing identified a recurrent somatic missense mutation JAK2V617F in granulocyte DNA samples of 121 of 164 PV patients, of which 41 had homozygous and 80 had heterozygous mutations. Molecular and cytogenetic analyses demonstrated that homozygous mutations were due to duplication of the mutant allele. JAK2V617F was also identified in granulocyte DNA samples from 37 of 115 ET and 16 of 46 MMM patients, but was not observed in 269 normal individuals. In vitro analysis demonstrated that JAK2V617F is a constitutively active tyrosine kinase.
Subfields: Genetics, Hematology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/7091fe539ed234c9eef290c9d7ef2c83c32f8d20
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- K. Ghoreschi
- Yana Pikman
- Benjamin H. Lee
- T. Mercher
- Elizabeth Mcdowell
- Liqun Yang
- M. Wadleigh
- A. Orazi
Citations in the corpus
- MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. (2006, neutral): “All patients 1182 735 252 13 447 335 7 MMM 290 198 106 (54) 8 (4) 92 46 (50) 5 (5) De novo NA 159 75 8 NA NA 4 After ET NA 10 8 0 NA NA 1 After PV NA 29 23 0 NA NA n/a ET 318 167 76 (46) 2 (1) 151 106 (70) 2 (1) PV 242 38 38 (100) 0 204 183 (90) 0 AML 126 126 29 (23) 3 (2) 0 n/a n/a With antecedent ”
- Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. (2007, methodology): “Similarly, we propose to replace the current list of B-criteria with 3 biologically relevant “minor” criteria: (1) MPD-consistent bone marrow histology, (2) serum erythropoietin level below the reference range for normal, and (3) presence of endogenous erythroid colonies.”
- Targeting cancer stem cell pathways for cancer therapy (2020, background): “315, 316 These disorders are caused by the overexpansion of hematopoietic precursors, which are often clonal and can result in leukemia.”
- Lessons from the cancer genome. (2013, neutral): “The studies quickly hit pay dirt, with the finding of mutations in BRAF in 50% of melanomas, PIK3CA in 25%–30% of breast and colorectal cancers, EFGR in 10%–15% of non-small cell lung cancers, FGFR2 in 15%–20% of endometrial cancers, and JAK2 in myeloproliferative diseases (Davies et al., 2002; Dutt”
- Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. (2005, neutral): “ET 59 24 (41) 15/9 65 (5-88) 35 (59) 23/12 56 (24-88) 4 (17)”
- JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. (2012, neutral): “Total 146 (100) 46 (32) 41 (28) 9 (6) 3 (2)”